Prevention and management of neurodegenerative disorders by an Ayurvedic formulation

Clinical Trial on role of an Ayurvedic formulation in the prevention and management of Neurodegenerative disorders

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/12/005312

Enrollment

1000

Registered

2014-12-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G- Mental Health Health Condition 2: null- Neurodegenerative disorder

Interventions

Intervention1: Herbal neuroprotective agent: 900 mg twice in day for 36 months Intervention2: Test formulation 500mg twice per day for a period of 1 year: The shade dried whole plant of Bacopa monnier

Eligibility

Inclusion criteria

Inclusion criteria: Willingness to give informed consent and a deterioration of memory along with at least three of the following five complaints: 1. Poor orientation 2. Poor judgement and problem solving difficulties 3. Trouble in the functioning of community affairs 4. Inability to function independently in home and during hobbies 5. Difficulties in personal care. Clinical screening for SDAT was done using dementia rating scale-II

Exclusion criteria

Exclusion criteria: Subjects suffering from any metabolic disease Established neuropathy or tuberculosis SDAT patients receiving conventional treatment were excluded from the study.

Design outcomes

Primary

Measure	Time frame
Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months);Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months);Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months);Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months);Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months)	—

Measure

Time frame

Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months);Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months);Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months);Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months);Improvement in cognitive function particularly memory performance including behavioral abnormalitiesTimepoint: Gradual improvement (3,6,9 and 12 months)

—

Secondary

Measure	Time frame
Effect on oxidative stress markers, anti-inflammatory activity, homocysteine lowering effects, improvement in attention span, new learning, orientation skill and improvement in sleep patternTimepoint: Gradual improvement (3,6,9 and 12 months)	—

Countries

India

Contacts

Public ContactDr Aruna Agrawal

Institute of Medical Sciences

gpdubey13@gmail.com9450963942

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026